The disclosure provides a recombinant cell capable of producing a steviol glycoside, wherein the cell comprises a nucleic acid coding for a variant of a parent polypeptide, wherein the variant has steviol glycoside transport mediating activity, wherein the variant comprises an amino acid sequence which, when aligned with the amino acid sequence of the parent polypeptide, comprises at least one modification of the amino acid residue corresponding to any of the amino acids in the amino acid sequence of the parent polypeptide, wherein the variant has an improved ability to produce rebaudioside M and optionally other steviol glycosides extracellularly if compared with the parent polypeptide when measured under the same conditions.

The disclosure provides a recombinant cell capable of producing a steviol glycoside, wherein the cell comprises a nucleic acid coding for a variant of a parent polypeptide, wherein the variant has steviol glycoside transport mediating activity, wherein the variant comprises an amino acid sequence which, when aligned with the amino acid sequence of the parent polypeptide, comprises at least one modification of the amino acid residue corresponding to any of the amino acids in the amino acid sequence of the parent polypeptide, wherein the variant has an improved ability to produce rebaudioside M and optionally other steviol glycosides extracellularly if compared with the parent polypeptide when measured under the same conditions.

Disclosed herein are modified strains for improving secretion of recombinantly expressed products secreted from a host organism with improved growth and productivity characteristics, as well as methods of using the modified strains.

The present invention is directed to a recombinant herpesvirus comprising a heterologous peptide and optionally polypeptide ligand capable of binding to (a) target molecule(s) and fused to or inserted into glycoprotein D. The recombinant herpesvirus may additionally comprise modifications for detargeting the virus from the natural receptors of gD. This allows the herpesvirus to efficiently target a cell for therapeutic purposes and a cell for virus production. The present invention further comprises a pharmaceutical composition comprising the herpesvirus, the herpesvirus for use in the treatment of a tumor, infection, degenerative disorder or senescence-associated disease, a nucleic acid and a vector coding for the gD, a polypeptide comprising the gD, and a cell comprising the herpesvirus, nucleic acid, vector or polypeptide. Moreover, a method for infecting a cell with the herpesvirus or for producing the herpesvirus is disclosed.

The present invention is directed to a recombinant herpesvirus comprising a heterologous peptide and optionally polypeptide ligand capable of binding to (a) target molecule(s) and fused to or inserted into glycoprotein D. The recombinant herpesvirus may additionally comprise modifications for detargeting the virus from the natural receptors of gD. This allows the herpesvirus to efficiently target a cell for therapeutic purposes and a cell for virus production. The present invention further comprises a pharmaceutical composition comprising the herpesvirus, the herpesvirus for use in the treatment of a tumor, infection, degenerative disorder or senescence-associated disease, a nucleic acid and a vector coding for the gD, a polypeptide comprising the gD, and a cell comprising the herpesvirus, nucleic acid, vector or polypeptide. Moreover, a method for infecting a cell with the herpesvirus or for producing the herpesvirus is disclosed.

The disclosure relates to the use of a mutant SSK1 gene encoding a truncated ssk1 protein for the construction of a mutant yeast strain with decreased glycerol production, when compared to the wild-type strain. It relates further to the use of such strains for high-yield bioethanol production, especially in high osmotic media, or on cellulosic hydrolysates, where normal yeast strains do produce a significant amount of glycerol.

The disclosure relates to the use of a mutant SSK1 gene encoding a truncated ssk1 protein for the construction of a mutant yeast strain with decreased glycerol production, when compared to the wild-type strain. It relates further to the use of such strains for high-yield bioethanol production, especially in high osmotic media, or on cellulosic hydrolysates, where normal yeast strains do produce a significant amount of glycerol.

What provided is a method for regulating in vitro biosynthesis activity by knocking-out of a nuclease system, comprising: screening five nucleases among numerous nucleases, and performing down-regulation or knocking-out on one of the five nucleases (e.g., EXN53). The method can improve the stability of nucleic acid and the protein production efficiency of an in vitro protein synthesis system.

What provided is a method for regulating in vitro biosynthesis activity by knocking-out of a nuclease system, comprising: screening five nucleases among numerous nucleases, and performing down-regulation or knocking-out on one of the five nucleases (e.g., EXN53). The method can improve the stability of nucleic acid and the protein production efficiency of an in vitro protein synthesis system.

Materials and methods that involve overexpression of a transcriptional activator such as retrograde regulation protein 1 (Rtg1) for increasing expression of one or more polypeptides.